

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PFIZER INC			2. Issuer Name and Ticker or Trading Symbol Cortexyme, Inc. [CRTX]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 05/13/2019			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input type="checkbox"/> <input checked="" type="checkbox"/> Form filed by More than One Reporting Person		
235 E 42ND ST			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street) NEW YORK NY 10017								
(City) (State) (Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/13/2019		C		2,360,071	A	\$0 ⁽¹⁾	2,360,071	D ⁽²⁾	
Common Stock	05/13/2019		C		215,697	A	\$0 ⁽¹⁾	2,575,768	D ⁽²⁾	
Common Stock	05/13/2019		C		624,205	A	\$0 ⁽¹⁾	3,199,973	D ⁽²⁾	
Common Stock	05/13/2019		P		50,000	A	\$17 ⁽³⁾	3,249,973	D ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Redeemable Convertible Preferred Stock	(1)	05/13/2019		C			2,360,071	(1)	(1)	Common Stock	2,360,071	\$0	0	D ⁽²⁾	
Series B Redeemable Convertible Preferred Stock	(1)	05/13/2019		C			215,697	(1)	(1)	Common Stock	215,697	\$0	0	D ⁽²⁾	
Series B Redeemable Convertible Preferred Stock	(1)	05/13/2019		C			624,205	(1)	(1)	Common Stock	624,205	\$0	0	D ⁽²⁾	

1. Name and Address of Reporting Person* PFIZER INC		
(Last)	(First)	(Middle)
235 E 42ND ST		
(Street) NEW YORK NY 10017		
(City)	(State)	(Zip)
1. Name and Address of Reporting Person* Pfizer Ventures (US) LLC		
(Last)	(First)	(Middle)
235 EAST 42ND STREET		
(Street) NEW YORK NY 10017		

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
Pfizer Strategic Investment Holdings LLC		
(Last)	(First)	(Middle)
235 EAST 42ND STREET		
(Street)		
NEW YORK	NY	10017
(City)	(State)	(Zip)

Explanation of Responses:

- Each share of the Series A Redeemable Convertible Preferred Common Stock ("Series A Preferred Stock"), which consists of 2,360,071 shares of Series A Preferred Stock held of record by Pfizer Ventures (US) LLC ("PVUS"), a controlled affiliate of Pfizer Inc. ("Pfizer"), and each share of the Series B Redeemable Convertible Preferred Stock ("Series B Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), which consists of (a) 215,697 shares of Series B Preferred Stock held of record by Pfizer Strategic Investment Holdings LLC, a controlled affiliate of Pfizer, and (b) 624,205 shares of Series B Preferred Stock held of record by Pfizer, converted into common stock of Cortexyme, Inc. (the "Issuer") on a one-for-one basis upon the closing of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.
- Each Reporting Person disclaims beneficial ownership of securities reported on this Form 4, except to the extent of its respective pecuniary interest therein.
- PVUS purchased 50,000 additional shares of common stock in the Issuer's initial public offering for consideration of \$17.00 per share.

[Pfizer Inc., By /s/ Susan Grant, Assistant Secretary](#) 05/14/2019

[Pfizer Ventures \(US\) LLC, By /s/ Susan Grant, Secretary](#) 05/14/2019

[Pfizer Strategic Investment Holdings LLC, By /s/ Susan Grant, Assistant Secretary](#) 05/14/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.